COVID-19 Vaccine and Development of Immune Thrombocytopenic Purpura
NCT05455983 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2022-07-13
Summary
Detect development of immune thrombocytopenic purpura (ITP) after different types of (COVID-19) vaccination
Conditions
- COVID-19 Vaccine
Interventions
- BIOLOGICAL
-
covid19 vaccines
different types of (COVID-19) vaccination
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Ahmed F Thabet, Professor · Assiut University
-
Rania M Hafez, Assist. Prof · Assiut University
-
Shymaa M Ismail, Doctor · Assiut University
Eligibility
- Min Age
- 17 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-08-01
- Primary Completion
- 2023-08-01
- Completion
- 2023-12-01
Countries
- Egypt
Study Locations
More Related Trials
-
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
NCT03002038 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
NCT04894253 ·Status: TERMINATED
-
Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus
NCT03179046 ·Status: COMPLETED
-
SLE Vasculitis In Egyptian Patients
NCT04386889 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Telitacicept in Early SLE
NCT05899907 ·Status: UNKNOWN ·Phase: PHASE4
-
The Frequency of Thiopurine Methyltransferase Polymorphism in Systemic Lupus Erythematosus SLE
NCT07012239 ·Status: COMPLETED
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806 ·Status: RECRUITING ·Phase: PHASE1
-
Optimization of Glucocorticoid Taper Strategies for SLE-ITP
NCT05506033 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia
NCT07298733 ·Status: NOT_YET_RECRUITING
-
The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage
NCT07136337 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Value of Uric Acid as Early Predictor of Lupus Nephritis
NCT05402735 ·Status: UNKNOWN
-
Antimalarial and Covid 19 in Rheumatoid Arthritis
NCT04389320 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
NCT00282347 ·Status: COMPLETED ·Phase: PHASE3
-
Haematological Indices in Systemic Lupus Erythematosus
NCT04110184 ·Status: UNKNOWN
-
Effect of Injectable Anticoagulants on Research for a Circulating Lupus-type Anticoagulant
NCT05416190 ·Status: COMPLETED ·Phase: NA
-
Assessment of Rituximab Therapeutic Response Versus Conventional Treatment
NCT05553496 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Monitoring of Inflammatory Conditions
NCT05458531 ·Status: COMPLETED
-
Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
NCT02949349 ·Status: COMPLETED ·Phase: PHASE2
-
Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis
NCT02453997 ·Status: COMPLETED
-
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
NCT01541670 ·Status: TERMINATED ·Phase: PHASE1
-
To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis
NCT00881309 ·Status: COMPLETED ·Phase: NA
-
Clinical Characteristic and MEFV Gene Mutations in Patient With Juvenile Onest Systemic Lupus Erythematosus
NCT04645225 ·Status: UNKNOWN
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
NCT05039619 ·Status: RECRUITING ·Phase: PHASE2
-
Measurement of Anti-dsDNA by Both CLIFT & ELISA
NCT03303508 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants
NCT05984251 ·Status: COMPLETED ·Phase: PHASE1